New drug combo targets resistant leukemia
NCT ID NCT06235801
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a combination of two drugs, gilteritinib and momelotinib, for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose of momelotinib when given with gilteritinib. About 20 participants will be enrolled at MD Anderson Cancer Center.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World data reveals how bosutinib fights leukemia outside clinical trials
- New drug cocktail aims to tame tough leukemias
- Promising combo targets Leukemia's genetic weakness
- New hope for hard-to-treat leukemia: old drug shows promise in combo therapy
- Exercise may turn back the clock for blood cancer survivors
- Exercise plus supplement may rebuild muscle in young transplant survivors